<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056026</url>
  </required_header>
  <id_info>
    <org_study_id>ProgenaBiome-001</org_study_id>
    <nct_id>NCT04056026</nct_id>
  </id_info>
  <brief_title>A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma</brief_title>
  <official_title>A Single Dose FMT Infusion From a Healthy Family Donor Via Colonoscopy as an Adjunct to Keytruda for the Benefit of Improving Efficacy of Immunotherapy for Metastatic Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProgenaBiome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProgenaBiome</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to ensure a favorable gut microbiome by fecal microbiota transplant
      to enhance the efficacy Keytruda
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have shown that a favorable microbiome can be the difference between response and
      non-response of certain cancer treatments such as PD-1 blockade inhibitors. As such the
      investigators propose to ensure a favorable microbiome in this patient by fecal microbiota
      transplant to enhance the efficacy of such a drug, Keytruda.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Actual">December 18, 2018</completion_date>
  <primary_completion_date type="Actual">December 18, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Five years</time_frame>
    <description>The time from transplant that the patient's tumors remain stable or shrink.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Fecal Microbiota Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will undergo fecal microbiota transplant. The 600cc of donor stool will be transplanted by colonoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplant</intervention_name>
    <description>Fecal material from a healthy family donor will be transplanted into the patient via colonoscopy</description>
    <arm_group_label>Fecal Microbiota Transplant</arm_group_label>
    <other_name>FMT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with metastatic mesothelioma deemed a candidate for PD-1 blockade inhibitor
             therapy

        Exclusion Criteria:

          -  Patient unable/unwilling to comply with protocol

          -  Patient deemed not a candidate for PD-1 Blockade inhibitor therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ProgenaBiome</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/full/10.1002/eji.201444972</url>
    <description>The role of the microbiota in inflammation, carcinogenesis, and cancer therapy</description>
  </link>
  <link>
    <url>http://cancerres.aacrjournals.org/content/early/2016/07/28/0008-5472.CAN-16-0448</url>
    <description>Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome</description>
  </link>
  <link>
    <url>https://www.microbiomeconference.com/blog/gut-bugs-may-modulate-the-efficacy-of-anti-pd1-immunotherapy</url>
    <description>Gut Bugs May Modulate the Efficacy of Anti-PD1 Immunotherapy</description>
  </link>
  <link>
    <url>https://www.europeanurology.com/article/S0302-2838(18)30422-6/fulltext</url>
    <description>Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial Tumors</description>
  </link>
  <link>
    <url>https://www.sciencedirect.com/science/article/abs/pii/S001650851830369X</url>
    <description>Could Fecal Transplantation Become Part of PD-1-Based Immunotherapy, Due to Effects of the Intestinal Microbiome?</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

